|
US6365178B1
(en)
*
|
1996-09-06 |
2002-04-02 |
Watson Pharmaceuticals, Inc. |
Method of making pressure sensitive adhesive matrix patches for transdermal drug delivery using hydrophilic salts of drugs and hydrophobic pressure sensitive adhesive dispersions
|
|
US5800832A
(en)
*
|
1996-10-18 |
1998-09-01 |
Virotex Corporation |
Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
|
|
US7629384B2
(en)
*
|
1997-09-17 |
2009-12-08 |
Strategic Science & Technologies, Llc |
Topical delivery of L-arginine to cause beneficial effects
|
|
US20050048102A1
(en)
*
|
1997-10-16 |
2005-03-03 |
Virotex Corporation |
Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces
|
|
EP1117389A1
(en)
*
|
1998-09-08 |
2001-07-25 |
TheraTech, Inc. |
Method of making pressure sensitive adhesive matrix patches containing hydrophilic salts of drugs
|
|
GB9828480D0
(en)
*
|
1998-12-24 |
1999-02-17 |
Dermatech Limited |
Transdermal drug delivery system
|
|
US6562368B2
(en)
|
1999-12-16 |
2003-05-13 |
Dermatrends, Inc. |
Transdermal administration of oxybutynin using hydroxide-releasing agents as permeation enhancers
|
|
US6602912B2
(en)
|
2000-06-30 |
2003-08-05 |
Dermatrends, Inc. |
Transdermal administration of phenylpropanolamine
|
|
US6558695B2
(en)
*
|
1999-12-16 |
2003-05-06 |
Dermatrends, Inc. |
Topical and transdermal administration of peptidyl drugs using hydroxide releasing agents as permeation enhancers
|
|
US6719997B2
(en)
|
2000-06-30 |
2004-04-13 |
Dermatrends, Inc. |
Transdermal administration of pharmacologically active amines using hydroxide-releasing agents as permeation enhancers
|
|
US6582724B2
(en)
*
|
1999-12-16 |
2003-06-24 |
Dermatrends, Inc. |
Dual enhancer composition for topical and transdermal drug delivery
|
|
US6645520B2
(en)
|
1999-12-16 |
2003-11-11 |
Dermatrends, Inc. |
Transdermal administration of nonsteroidal anti-inflammatory drugs using hydroxide-releasing agents as permeation enhancers
|
|
US6562369B2
(en)
|
1999-12-16 |
2003-05-13 |
Dermatrends, Inc. |
Transdermal administration of androgenic drugs hydroxide-releasing agents as permeation enhancers
|
|
US6562370B2
(en)
|
1999-12-16 |
2003-05-13 |
Dermatrends, Inc. |
Transdermal administration of steroid drugs using hydroxide-releasing agents as permeation enhancers
|
|
US6565879B1
(en)
|
1999-12-16 |
2003-05-20 |
Dermatrends, Inc. |
Topical and transdermal administration of peptidyl drugs with hydroxide-releasing agents as skin permeation enhancers
|
|
US6586000B2
(en)
*
|
1999-12-16 |
2003-07-01 |
Dermatrends, Inc. |
Hydroxide-releasing agents as skin permeation enhancers
|
|
US20030104041A1
(en)
*
|
1999-12-16 |
2003-06-05 |
Tsung-Min Hsu |
Transdermal and topical administration of drugs using basic permeation enhancers
|
|
US6673363B2
(en)
*
|
1999-12-16 |
2004-01-06 |
Dermatrends, Inc. |
Transdermal and topical administration of local anesthetic agents using basic enhancers
|
|
US7897140B2
(en)
|
1999-12-23 |
2011-03-01 |
Health Research, Inc. |
Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
|
|
US7166719B2
(en)
|
2002-06-27 |
2007-01-23 |
Health Research, Inc. |
Fluorinated photosensitizers related to chlorins and bacteriochlorins for photodynamic therapy
|
|
DE10004790B4
(de)
*
|
2000-02-01 |
2004-09-09 |
Lts Lohmann Therapie-Systeme Ag |
Transdermales therapeutisches System zur Verabreichung von Zaleplon, Verfahren zu seiner Herstellung und seine Verwendung
|
|
US6518359B1
(en)
|
2000-02-25 |
2003-02-11 |
3M Innovative Properties Co. |
Polyurethane-based pressure-sensitive adhesives, systems for such adhesives, articles therefrom, and methods of making
|
|
US6642304B1
(en)
|
2000-02-25 |
2003-11-04 |
3M Innovative Properties Company |
Polyurethane-based adhesives, systems for such adhesives, articles therefrom, and methods of making
|
|
US7029694B2
(en)
|
2000-04-26 |
2006-04-18 |
Watson Laboratories, Inc. |
Compositions and methods for transdermal oxybutynin therapy
|
|
US7179483B2
(en)
*
|
2000-04-26 |
2007-02-20 |
Watson Pharmaceuticals, Inc. |
Compositions and methods for transdermal oxybutynin therapy
|
|
US20030124177A1
(en)
*
|
2000-04-26 |
2003-07-03 |
Watson Pharmaceuticals, Inc. |
Compositions and methods for transdermal oxybutynin therapy
|
|
EP2322170A1
(en)
*
|
2000-04-26 |
2011-05-18 |
Watson Pharmaceuticals, Inc. |
Minimizing adverse experience associated with oxybutynin therapy
|
|
US20020119187A1
(en)
*
|
2000-09-29 |
2002-08-29 |
Cantor Adam S. |
Composition for the transdermal delivery of fentanyl
|
|
KR100732948B1
(ko)
*
|
2000-11-22 |
2007-06-27 |
아이큐어 주식회사 |
국소마취용 패취
|
|
DK1381352T3
(da)
*
|
2001-03-16 |
2007-07-09 |
Alza Corp |
Plaster til transdermal indgivelse af fentanyl
|
|
DE20221247U1
(de)
|
2001-03-16 |
2005-09-15 |
Alza Corp |
Transdermal-Pflaster zum Verabreichen von Fentanyl
|
|
US20050208117A1
(en)
*
|
2001-03-16 |
2005-09-22 |
Venkatraman Subramanian S |
Transdermal administration of fentanyl and analogs thereof
|
|
PL368612A1
(en)
*
|
2001-08-14 |
2005-04-04 |
Biotie Therapies Corporation |
Method of treating alcoholism or alcohol abuse
|
|
DE10141650C1
(de)
|
2001-08-24 |
2002-11-28 |
Lohmann Therapie Syst Lts |
Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
|
|
EP1446110A2
(en)
*
|
2001-10-16 |
2004-08-18 |
Structural Bioinformatics Inc. |
Organosulfur inhibitors of tyrosine phosphatases
|
|
US20030124178A1
(en)
*
|
2001-12-28 |
2003-07-03 |
Haley Jeffrey T. |
Soft, adherent, soluble oral patch
|
|
US20050226915A1
(en)
*
|
2001-12-28 |
2005-10-13 |
Oramelts Corporation, A Washington Corporation |
Method for manufacturing and packaging oral patches with rounded edges
|
|
US7022342B2
(en)
|
2002-03-28 |
2006-04-04 |
Andrx Corporation, Inc. |
Controlled release oral dosage form of beta-adrenergic blocking agents
|
|
CA2496454A1
(en)
|
2002-04-23 |
2003-11-06 |
Alza Corporation |
Transdermal analgesic systems with reduced abuse potential
|
|
DK1530469T3
(da)
*
|
2002-08-20 |
2009-05-04 |
Euro Celtique Sa |
Transdermal dosisform omfattende et aktivt middel og et salt og fri baseform af en antagonist
|
|
US20040086551A1
(en)
*
|
2002-10-30 |
2004-05-06 |
Miller Kenneth J. |
Fentanyl suspension-based silicone adhesive formulations and devices for transdermal delivery of fentanyl
|
|
CL2004000927A1
(es)
|
2003-04-30 |
2005-01-28 |
Purdue Pharma Lp |
Forma de dosificacion transdermica que comprende un agente activo, una superficie proxima y una superficie distal.
|
|
US8790689B2
(en)
|
2003-04-30 |
2014-07-29 |
Purdue Pharma L.P. |
Tamper resistant transdermal dosage form
|
|
US7182955B2
(en)
*
|
2003-04-30 |
2007-02-27 |
3M Innovative Properties Company |
Abuse-resistant transdermal dosage form
|
|
US20040219195A1
(en)
*
|
2003-04-30 |
2004-11-04 |
3M Innovative Properties Company |
Abuse-resistant transdermal dosage form
|
|
KR20060023529A
(ko)
*
|
2003-05-14 |
2006-03-14 |
토레이파인스 테라퓨틱스, 인코포레이티드 |
화합물 및 아밀로이드 베타를 변조하는데 있어서 그의 용도
|
|
US20080020028A1
(en)
*
|
2003-08-20 |
2008-01-24 |
Euro-Celtique S.A. |
Transdermal dosage form comprising an active agent and a salt and a free-base form of an adverse agent
|
|
CA2543610A1
(en)
|
2003-10-30 |
2005-05-19 |
Alza Corporation |
Transdermal analgesic systems having reduced abuse potential
|
|
US20050137375A1
(en)
*
|
2003-12-19 |
2005-06-23 |
3M Innovative Properties Company |
Polyurethane-based pressure sensitive adhesives and methods of manufacture
|
|
WO2005090370A1
(en)
|
2004-02-05 |
2005-09-29 |
The Regents Of The University Of California |
Pharmacologically active agents containing esterified phosphonates and methods for use thereof
|
|
AU2005235308B2
(en)
*
|
2004-04-19 |
2011-12-01 |
Strategic Science & Technologies, Llc |
Transdermal delivery of beneficial substances effected by a hostile biophysical environment
|
|
US9226909B2
(en)
|
2004-04-19 |
2016-01-05 |
Strategic Science & Technologies, Llc |
Beneficial effects of increasing local blood flow
|
|
AU2005244999A1
(en)
|
2004-05-20 |
2005-12-01 |
The Scripps Research Institute |
Transthyretin stabilization
|
|
US7666914B2
(en)
*
|
2004-06-03 |
2010-02-23 |
Richlin David M |
Topical preparation and method for transdermal delivery and localization of therapeutic agents
|
|
EP1765332A2
(en)
*
|
2004-06-17 |
2007-03-28 |
Cengent Therapeutics, Inc. |
Trisubstituted nitrogen modulators of tyrosine phosphatases
|
|
EP1786421A2
(en)
*
|
2004-07-09 |
2007-05-23 |
Cengent Therapeutics, Inc. |
Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases
|
|
JP4745747B2
(ja)
|
2004-08-12 |
2011-08-10 |
日東電工株式会社 |
フェンタニル含有貼付製剤
|
|
JP4824963B2
(ja)
*
|
2004-08-12 |
2011-11-30 |
日東電工株式会社 |
貼付材及び貼付製剤
|
|
KR20070053267A
(ko)
*
|
2004-08-20 |
2007-05-23 |
쓰리엠 이노베이티브 프로퍼티즈 컴파니 |
반투명 보호 필름을 갖는 경피 약물 전달 장치
|
|
WO2006028970A1
(en)
*
|
2004-09-02 |
2006-03-16 |
Cengent Therapeutics, Inc. |
Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases
|
|
JP5001843B2
(ja)
|
2004-09-17 |
2012-08-15 |
ホワイトヘッド インスティテュート フォー バイオメディカル リサーチ |
α−シヌクレイン毒性を阻害する化合物、組成物および方法
|
|
US20060134201A1
(en)
*
|
2004-12-16 |
2006-06-22 |
Haley Jeffrey T |
Collagen troches for treating mouth lesions
|
|
TW200640526A
(en)
*
|
2005-02-24 |
2006-12-01 |
Alza Corp |
Transdermal electrotransport drug delivery systems with reduced abuse potential
|
|
US8222257B2
(en)
|
2005-04-01 |
2012-07-17 |
The Regents Of The University Of California |
Phosphono-pent-2-en-1-yl nucleosides and analogs
|
|
WO2006134937A1
(ja)
*
|
2005-06-14 |
2006-12-21 |
Sekisui Chemical Co., Ltd. |
皮膚外用剤
|
|
WO2007002109A2
(en)
*
|
2005-06-20 |
2007-01-04 |
The Regents Of The University Of California |
Multidentate pyrone-derived chelators for medicinal imaging and chelation
|
|
US10137135B2
(en)
|
2005-08-15 |
2018-11-27 |
Allergan Sales, Llc |
Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith
|
|
US20080058282A1
(en)
|
2005-08-30 |
2008-03-06 |
Fallon Joan M |
Use of lactulose in the treatment of autism
|
|
US8492428B2
(en)
*
|
2005-09-20 |
2013-07-23 |
Mayo Foundation For Medical Education And Research |
Small-molecule botulinum toxin inhibitors
|
|
EP1937226A2
(en)
*
|
2005-09-23 |
2008-07-02 |
Alza Corporation |
Transdermal galantamine delivery system
|
|
EP1948142B1
(en)
|
2005-09-23 |
2014-04-09 |
ALZA Corporation |
High enhancer-loading polyacrylate formulation for transdermal applications
|
|
US20070098772A1
(en)
*
|
2005-09-23 |
2007-05-03 |
Westcott Tyler D |
Transdermal norelgestromin delivery system
|
|
WO2007059979A2
(en)
*
|
2005-11-23 |
2007-05-31 |
Universität Zürich |
Allergy treatment by epicutaneous allergen administration
|
|
US8349120B2
(en)
*
|
2006-03-07 |
2013-01-08 |
Ora Health Corporation |
Multi-layer patch made on a sheet and enclosed in a blister
|
|
JP2009531443A
(ja)
*
|
2006-03-29 |
2009-09-03 |
フォールドアールエックス ファーマシューティカルズ インコーポレーティッド |
α−シヌクレイン毒性の抑制
|
|
DE102006019293A1
(de)
*
|
2006-04-21 |
2007-10-25 |
LABTEC Gesellschaft für technologische Forschung und Entwicklung mbH |
Pflaster, enthaltend ein Fentanyl Analogum
|
|
US20070248655A1
(en)
*
|
2006-04-21 |
2007-10-25 |
Haley Jeffrey T |
Lenticular shaped protective mouth sore discs
|
|
US20070248654A1
(en)
*
|
2006-04-21 |
2007-10-25 |
Haley Jeffrey T |
Protective mouth sore discs made with corn starch
|
|
EP3067044B1
(en)
|
2006-07-21 |
2019-03-27 |
BioDelivery Sciences International, Inc. |
Transmucosal delivery devices with enhanced uptake
|
|
MY162024A
(en)
|
2006-08-28 |
2017-05-31 |
La Jolla Inst Allergy & Immunology |
Antagonistic human light-specific human monoclonal antibodies
|
|
WO2008115811A2
(en)
*
|
2007-03-16 |
2008-09-25 |
Endo Pharmaceuticals, Inc. |
Transdermal delivery form disposal systems and methods
|
|
WO2008144320A2
(en)
*
|
2007-05-17 |
2008-11-27 |
Endo Pharmaceuticals, Inc. |
Opioid and methods of making and using the same
|
|
US20090264421A1
(en)
*
|
2007-10-05 |
2009-10-22 |
Bible Keith C |
Methods and Compositions for Treating Cancer
|
|
MY188123A
(en)
|
2007-10-15 |
2021-11-22 |
Alza Corp |
Once-a-day replacement transdermal administration of fentanyl
|
|
EP2222160B1
(en)
*
|
2007-11-21 |
2015-03-18 |
Pharmaxis Ltd. |
Haloallylamine inhibitors of ssao/vap-1 and uses therefor
|
|
EP2259780A2
(en)
|
2008-02-28 |
2010-12-15 |
Syntropharma Limited |
Pharmaceutical composition comprising naltrexone
|
|
US8658163B2
(en)
|
2008-03-13 |
2014-02-25 |
Curemark Llc |
Compositions and use thereof for treating symptoms of preeclampsia
|
|
US8084025B2
(en)
|
2008-04-18 |
2011-12-27 |
Curemark Llc |
Method for the treatment of the symptoms of drug and alcohol addiction
|
|
US11016104B2
(en)
|
2008-07-01 |
2021-05-25 |
Curemark, Llc |
Methods and compositions for the treatment of symptoms of neurological and mental health disorders
|
|
US20100221313A1
(en)
*
|
2008-12-01 |
2010-09-02 |
Innovative Pharmaceuticals, Llc |
Transdermal reservoir patch
|
|
NZ593831A
(en)
|
2009-01-06 |
2013-09-27 |
Curelon Llc |
Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces
|
|
NZ593823A
(en)
|
2009-01-06 |
2013-09-27 |
Curelon Llc |
Compositions and methods for the treatment or the prevention of infections by e. coli
|
|
SG173852A1
(en)
*
|
2009-02-27 |
2011-09-29 |
Ambit Biosciences Corp |
Jak kinase modulating quinazoline derivatives and methods of use thereof
|
|
WO2010111346A2
(en)
*
|
2009-03-24 |
2010-09-30 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Hep-lock and iv site dry mitt
|
|
US9056050B2
(en)
|
2009-04-13 |
2015-06-16 |
Curemark Llc |
Enzyme delivery systems and methods of preparation and use
|
|
CA2766354C
(en)
|
2009-06-24 |
2019-08-13 |
Strategic Science & Technologies, Llc |
Topical compositions containing ibuprofen or sildenafil
|
|
EP2445493A1
(en)
|
2009-06-24 |
2012-05-02 |
Strategic Science & Technologies, LLC |
Topical composition containing naproxen
|
|
US11684624B2
(en)
|
2009-06-24 |
2023-06-27 |
Strategic Science & Technologies, Llc |
Treatment of erectile dysfunction and other indications
|
|
US8404728B2
(en)
|
2009-07-30 |
2013-03-26 |
Mayo Foundation For Medical Education And Research |
Small-molecule botulinum toxin inhibitors
|
|
WO2011057214A2
(en)
|
2009-11-09 |
2011-05-12 |
Neurogenetic Pharmaceuticals, Inc. |
Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor
|
|
US20110301235A1
(en)
|
2009-12-02 |
2011-12-08 |
Alquest Therapeutics, Inc. |
Organoselenium compounds and uses thereof
|
|
SG181896A1
(en)
|
2009-12-23 |
2012-07-30 |
Map Pharmaceuticals Inc |
Novel ergoline analogs
|
|
WO2011130455A1
(en)
|
2010-04-13 |
2011-10-20 |
Najib Babul |
Dermal pharmaceutical compositions of 1-methyl-2',6'-pipecoloxylidide and method of use
|
|
EP2658551B1
(en)
|
2010-12-29 |
2020-07-01 |
Strategic Science & Technologies, LLC |
Treatment of erectile dysfunction and other indications
|
|
CN105878172A
(zh)
|
2010-12-29 |
2016-08-24 |
战略科学与技术有限责任公司 |
治疗变态反应和其它适应症的系统和方法
|
|
GB2503852B
(en)
|
2011-04-21 |
2018-12-12 |
Curemark Llc |
Compounds for the treatment of neuropsychiatric disorders
|
|
US11786455B2
(en)
|
2011-05-10 |
2023-10-17 |
Itochu Chemical Frontier Corporation |
Non-aqueous patch
|
|
US9925264B2
(en)
|
2011-05-10 |
2018-03-27 |
Itochu Chemical Frontier Corporation |
Non-aqueous patch
|
|
ES2743524T3
(es)
|
2011-05-10 |
2020-02-19 |
Itochu Chemical Frontier Corp |
Parche no acuoso
|
|
BR112013033339A2
(pt)
|
2011-06-23 |
2016-08-16 |
Map Pharmaceuticals Inc |
análogos de fluorergolina
|
|
SG10201610097WA
(en)
|
2011-08-18 |
2017-01-27 |
Biodelivery Sciences Int Inc |
Abuse-resistant mucoadhesive devices for delivery of buprenorphine
|
|
WO2013037482A1
(en)
|
2011-09-15 |
2013-03-21 |
Phenex Pharmaceuticals Ag |
Farnesoid x receptor agonists for cancer treatment and prevention
|
|
PT2823815T
(pt)
|
2011-09-27 |
2018-10-22 |
Itochu Chemical Frontier Corp |
Sistema transdérmico não aquoso
|
|
CA2790749A1
(en)
*
|
2011-09-29 |
2013-03-29 |
Nitto Denko Corporation |
Manufacturing method of patch preparation
|
|
AU2012355982A1
(en)
|
2011-12-19 |
2014-07-10 |
Map Pharmaceuticals, Inc. |
Novel iso-ergoline derivatives
|
|
US9901539B2
(en)
|
2011-12-21 |
2018-02-27 |
Biodelivery Sciences International, Inc. |
Transmucosal drug delivery devices for use in chronic pain relief
|
|
US8946420B2
(en)
|
2011-12-21 |
2015-02-03 |
Map Pharmaceuticals, Inc. |
Neuromodulatory compounds
|
|
DK2844637T5
(en)
|
2012-05-02 |
2018-08-13 |
Boehringer Ingelheim Int |
SUBSTITUTED 3-HALOALLYLAMINE INHIBITORS BY SSAO AND USES THEREOF
|
|
US10350278B2
(en)
|
2012-05-30 |
2019-07-16 |
Curemark, Llc |
Methods of treating Celiac disease
|
|
EP3406598B1
(en)
|
2012-06-14 |
2020-01-29 |
Mayo Foundation for Medical Education and Research |
Pyrazole derivatives as inhibitors of stat3
|
|
US9012640B2
(en)
|
2012-06-22 |
2015-04-21 |
Map Pharmaceuticals, Inc. |
Cabergoline derivatives
|
|
US9364273B2
(en)
*
|
2012-08-15 |
2016-06-14 |
DePuy Synthes Products, Inc. |
Drug eluting surgical screw
|
|
US9074186B2
(en)
|
2012-08-15 |
2015-07-07 |
Boston Medical Center Corporation |
Production of red blood cells and platelets from stem cells
|
|
WO2014068600A1
(en)
|
2012-11-02 |
2014-05-08 |
Zydus Technologies Limited |
Stable transdermal pharmaceutical drug delivery system comprising diclofenac
|
|
BR112015014964A2
(pt)
|
2012-12-21 |
2017-07-11 |
Map Pharmaceuticals Inc |
novos derivados de metisergida
|
|
US9169214B2
(en)
|
2012-12-21 |
2015-10-27 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
|
|
SG10201708143QA
(en)
|
2013-06-06 |
2017-11-29 |
Pierre Fabre Medicament |
Anti-c10orf54 antibodies and uses thereof
|
|
WO2014210504A1
(en)
*
|
2013-06-28 |
2014-12-31 |
Mitroo Sumair |
Tape having transdermal analgesic properties
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
LT3148579T
(lt)
|
2014-05-28 |
2021-05-25 |
Agenus Inc. |
Anti-gitr antikūnai ir jų panaudojimo būdai
|
|
EP3169317B1
(en)
|
2014-07-18 |
2020-04-08 |
Buzzz Pharmaceuticals Limited |
Oxymorphone transdermal patch
|
|
EP3179857B1
(en)
|
2014-08-14 |
2021-09-08 |
Mamoun M. Alhamadsheh |
Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life
|
|
KR102693806B1
(ko)
|
2014-12-11 |
2024-08-09 |
피에르 파브르 메디카먼트 |
항-c10orf54 항체들 및 그들의 용도들
|
|
CN107106510A
(zh)
*
|
2014-12-18 |
2017-08-29 |
Icure药品株式会社 |
含有多奈哌齐为有效成分的经皮吸收制剂
|
|
JP7211703B2
(ja)
|
2014-12-22 |
2023-01-24 |
ザ ロックフェラー ユニバーシティー |
抗ｍｅｒｔｋアゴニスト抗体及びその使用
|
|
US10010543B1
(en)
|
2014-12-23 |
2018-07-03 |
Barr Laboratories, Inc. |
Transdermal dosage form
|
|
MX2017009405A
(es)
|
2015-01-20 |
2018-01-18 |
Xoc Pharmaceuticals Inc |
Compuestos de tipo ergolina y usos de estos.
|
|
US9676776B2
(en)
|
2015-01-20 |
2017-06-13 |
Xoc Pharmaceuticals, Inc. |
Isoergoline compounds and uses thereof
|
|
CA2968642A1
(en)
|
2015-03-03 |
2016-09-09 |
Kymab Limited |
Antibodies, uses & methods
|
|
EP3289104B1
(en)
|
2015-04-29 |
2020-11-04 |
New York University |
Method for treating high-grade gliomas
|
|
SI3303394T1
(sl)
|
2015-05-29 |
2020-10-30 |
Agenus Inc. |
Protitelesa proti-CTLA-4 in postopki njihove uporabe
|
|
CA2993432A1
(en)
|
2015-09-01 |
2017-03-09 |
Agenus Inc. |
Anti-pd-1 antibodies and methods of use thereof
|
|
US10112924B2
(en)
|
2015-12-02 |
2018-10-30 |
Astraea Therapeutics, Inc. |
Piperdinyl nociceptin receptor compounds
|
|
KR20240132125A
(ko)
|
2015-12-02 |
2024-09-02 |
아스트레아 테라퓨틱스 엘엘씨 |
피페리디닐 노시셉틴 수용체 화합물
|
|
US10960013B2
(en)
|
2016-03-04 |
2021-03-30 |
East Carolina University |
J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders
|
|
WO2017156183A1
(en)
|
2016-03-08 |
2017-09-14 |
Los Gatos Pharmaceuticals, Inc. |
Camptothecin derivatives and uses thereof
|
|
US10064855B2
(en)
|
2016-03-08 |
2018-09-04 |
Los Gatos Pharmaceuticals, Inc. |
Composite nanoparticles and uses thereof
|
|
WO2017180794A1
(en)
|
2016-04-13 |
2017-10-19 |
Skyline Antiinfectives, Inc. |
Deuterated o-sulfated beta-lactam hydroxamic acids and deuterated n-sulfated beta-lactams
|
|
US20190160052A1
(en)
|
2016-05-13 |
2019-05-30 |
Institut Pasteur |
Inhibition of beta-2 nicotinic acetylcholine receptors to treat alzheimer's disease pathology
|
|
KR102366813B1
(ko)
|
2016-05-27 |
2022-02-24 |
아게누스 인코포레이티드 |
항-tim-3 항체 및 이의 사용 방법
|
|
AU2017292184A1
(en)
|
2016-07-08 |
2019-02-07 |
Staten Biotechnology B.V. |
Anti-Apoc3 antibodies and methods of use thereof
|
|
WO2018035281A1
(en)
|
2016-08-17 |
2018-02-22 |
North Carolina State University |
Northern-southern route to synthesis of bacteriochlorins
|
|
SG10201912663YA
(en)
|
2016-10-11 |
2020-03-30 |
Agenus Inc |
Anti-lag-3 antibodies and methods of use thereof
|
|
US11779604B2
(en)
|
2016-11-03 |
2023-10-10 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses and methods
|
|
AU2017353939A1
(en)
|
2016-11-07 |
2019-06-06 |
Neuracle Science Co., Ltd. |
Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
|
|
US10106521B2
(en)
|
2016-11-09 |
2018-10-23 |
Phloronol, Inc. |
Eckol derivatives, methods of synthesis and uses thereof
|
|
US10836774B2
(en)
|
2016-11-30 |
2020-11-17 |
North Carolina State University |
Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds
|
|
KR102504605B1
(ko)
|
2016-12-07 |
2023-03-02 |
아게누스 인코포레이티드 |
항-ctla-4 항체 및 이의 사용 방법
|
|
KR102603681B1
(ko)
|
2016-12-07 |
2023-11-17 |
아게누스 인코포레이티드 |
항체 및 이의 사용방법
|
|
BR112019017260A2
(pt)
|
2017-02-17 |
2020-04-14 |
Camris Int Inc |
antiveneno universal
|
|
KR102665258B1
(ko)
|
2017-02-17 |
2024-05-10 |
에이도스 테라퓨틱스, 인코포레이티드 |
Ag-10, 이의 중간체, 및 이의 염을 제조하는 방법
|
|
CA3059366A1
(en)
|
2017-04-13 |
2018-10-18 |
Agenus Inc. |
Anti-cd137 antibodies and methods of use thereof
|
|
CA3059133A1
(en)
|
2017-04-21 |
2018-10-25 |
Staten Biotechnology B.V. |
Anti-apoc3 antibodies and methods of use thereof
|
|
PT3618863T
(pt)
|
2017-05-01 |
2023-08-23 |
Agenus Inc |
Anticorpos anti-tigit e seus métodos de utilização
|
|
US10085999B1
(en)
|
2017-05-10 |
2018-10-02 |
Arixa Pharmaceuticals, Inc. |
Beta-lactamase inhibitors and uses thereof
|
|
CN111132980A
(zh)
|
2017-06-01 |
2020-05-08 |
Xoc制药股份有限公司 |
用于医学的麦角灵衍生物
|
|
JP2020525459A
(ja)
|
2017-06-26 |
2020-08-27 |
アンスティテュ・パストゥール |
Ｈｉｖリザーバーを排除し、ウイルス負荷を低減する処置
|
|
CA3067923A1
(en)
|
2017-06-27 |
2019-01-03 |
Neuracle Science Co., Ltd. |
Anti-fam19a5 antibodies and uses thereof
|
|
US11155613B2
(en)
|
2017-06-27 |
2021-10-26 |
Neuracle Science Co., Ltd. |
Use of anti-FAM19A5 antibodies for treating fibrosis
|
|
KR102454460B1
(ko)
|
2017-06-27 |
2022-10-17 |
주식회사 뉴라클사이언스 |
암 치료를 위한 항-fam19a5 항체의 용도
|
|
EP3645044A4
(en)
|
2017-06-27 |
2021-04-28 |
Neuracle Science Co., Ltd |
USE OF ANTI-FAMILY WITH SEQUENCE SIMILARITY 19, ELEMENT A5 ANTIBODIES TO TREAT GLAUCOMA
|
|
ES2953032T3
(es)
|
2017-09-01 |
2023-11-07 |
Univ East Carolina |
Métodos ex vivo para la activación de las células inmunológicas
|
|
KR102344589B1
(ko)
|
2017-10-02 |
2021-12-30 |
주식회사 뉴라클사이언스 |
기분 장애의 치료 및 진단을 위한 항-서열 유사성 19를 가진 패밀리, 멤버 a5 항체의 용도
|
|
BR112020008514A2
(pt)
|
2017-10-31 |
2020-10-20 |
Staten Biotechnology B.V. |
anticorpos anti-apoc3 e métodos de uso dos mesmos
|
|
US20190175519A1
(en)
*
|
2017-12-08 |
2019-06-13 |
Teikoku Pharma Usa, Inc. |
Naloxone Transdermal Delivery Devices and Methods for Using the Same
|
|
TWI817999B
(zh)
|
2018-03-23 |
2023-10-11 |
美商文涵治療有限公司 |
使用ag10治療ttr澱粉樣沉積症之方法
|
|
EP3823986A4
(en)
|
2018-04-24 |
2022-03-23 |
Neuracle Science Co., Ltd |
USE OF ANTIBODIES DIRECTED AGAINST SEQUENCE FAMILY 19, ELEMENT A5, FOR THE TREATMENT OF NEUROPATHIC PAIN
|
|
CN112119091A
(zh)
|
2018-05-10 |
2020-12-22 |
纽洛可科学有限公司 |
抗序列相似家族19成员a5的抗体及其使用方法
|
|
WO2020009685A1
(en)
|
2018-07-02 |
2020-01-09 |
John Tang |
Transdermal dosage form
|
|
WO2020008370A1
(en)
|
2018-07-02 |
2020-01-09 |
Clexio Biosciences Ltd. |
Transdermal patch
|
|
WO2020008366A1
(en)
|
2018-07-02 |
2020-01-09 |
Clexio Biosciences Ltd. |
Transdermal dosage form
|
|
US20230243836A1
(en)
|
2018-07-20 |
2023-08-03 |
Pierre Fabre Medicament |
Receptor for vista
|
|
MA53238A
(fr)
|
2018-08-17 |
2022-04-13 |
Eidos Therapeutics Inc |
Formules d'ag10
|
|
CA3113575A1
(en)
|
2018-10-03 |
2020-04-09 |
Staten Biotechnology B.V. |
Antibodies specific for human and cynomolgus apoc3 and methods of use thereof
|
|
WO2020102728A1
(en)
|
2018-11-16 |
2020-05-22 |
Neoimmunetech, Inc. |
Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor
|
|
WO2020128033A1
(en)
|
2018-12-20 |
2020-06-25 |
Institut Pasteur |
Cellular metabolism of hiv-1 reservoir seeding in cd4+ t cells
|
|
EP3921038A1
(en)
|
2019-02-06 |
2021-12-15 |
Dice Alpha, Inc. |
Il-17a modulators and uses thereof
|
|
WO2020176497A1
(en)
|
2019-02-26 |
2020-09-03 |
Rgenix, Inc. |
High-affinity anti-mertk antibodies and uses thereof
|
|
JP2022532924A
(ja)
|
2019-05-20 |
2022-07-20 |
ニルバナ サイエンシーズ インク． |
発光波長の範囲が狭い発光染料、それを含む組成物及びそれを製造及び使用する方法
|
|
BR112022003740A2
(pt)
|
2019-08-30 |
2022-05-31 |
Agenus Inc |
Anticorpos anti-cd96 e métodos de uso dos mesmos
|
|
JP7566889B2
(ja)
|
2019-09-16 |
2024-10-15 |
ダイス・アルファ・インコーポレイテッド |
Ｉｌ－１７ａモジュレーターおよびその使用
|
|
JP2023512456A
(ja)
|
2020-01-13 |
2023-03-27 |
ネオイミューンテック， インコーポレイテッド |
Ｉｌ－７タンパク質と二重特異性抗体の組み合わせで腫瘍を治療する方法
|
|
EP4100045A1
(en)
|
2020-02-05 |
2022-12-14 |
Washington University |
Method of treating a solid tumor with a combination of an il-7 protein and car-bearing immune cells
|
|
WO2021202329A1
(en)
*
|
2020-03-30 |
2021-10-07 |
Shinkei Therapeutics Llc |
Transdermal delivery of dextromethorphan
|
|
GB2593902B
(en)
|
2020-04-07 |
2022-04-13 |
Actimed Therapeutics Ltd |
Salt of a pharmaceutical compound
|
|
WO2022006228A1
(en)
|
2020-06-30 |
2022-01-06 |
Prosetta Biosciences, Inc. |
Isoquinoline derivatives, methods of synthesis and uses thereof
|
|
US11541009B2
(en)
|
2020-09-10 |
2023-01-03 |
Curemark, Llc |
Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
|
|
WO2022093718A1
(en)
|
2020-10-26 |
2022-05-05 |
Neoimmunetech, Inc. |
Methods of inducing stem cell mobilization
|
|
KR20230104176A
(ko)
|
2020-11-02 |
2023-07-07 |
네오이뮨텍, 인코퍼레이티드 |
코로나바이러스의 치료를 위한 인터류킨-7의 용도
|
|
US20240115675A1
(en)
|
2020-11-05 |
2024-04-11 |
Neoimmunetech, Inc. |
Method of treating a tumor with a combination of an il-7 protein and a nucleotide vaccine
|
|
CN117642396A
(zh)
|
2021-03-10 |
2024-03-01 |
戴斯分子Sv有限公司 |
αVβ6和αVβ1整联蛋白抑制剂及其用途
|
|
WO2022263357A1
(en)
|
2021-06-14 |
2022-12-22 |
Argenx Iip Bv |
Anti-il-9 antibodies and methods of use thereof
|
|
AU2022368836A1
(en)
|
2021-10-22 |
2024-05-02 |
Prosetta Biosciences, Inc. |
Novel host-targeted pan-respiratory antiviral small molecule therapeutics
|
|
CA3237696A1
(en)
|
2021-11-08 |
2023-05-11 |
Progentos Therapeutics, Inc. |
Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
|
|
EP4456907A1
(en)
|
2021-12-30 |
2024-11-06 |
NeoImmuneTech, Inc. |
Method of treating a tumor with a combination of il-7 protein and vegf antagonist
|
|
EP4433040A2
(en)
|
2022-01-03 |
2024-09-25 |
Lilac Therapeutics, Inc. |
Acyclic thiol prodrugs
|
|
US11932665B2
(en)
|
2022-01-03 |
2024-03-19 |
Lilac Therapeutics, Inc. |
Cyclic thiol prodrugs
|
|
GB2619907A
(en)
|
2022-04-01 |
2023-12-27 |
Kanna Health Ltd |
Novel crystalline salt forms of mesembrine
|
|
WO2024086852A1
(en)
|
2022-10-21 |
2024-04-25 |
Diagonal Therapeutics Inc. |
Heteromeric agonistic antibodies to il-18 receptor
|
|
WO2024102722A1
(en)
|
2022-11-07 |
2024-05-16 |
Neoimmunetech, Inc. |
Methods of treating a tumor with an unmethylated mgmt promoter
|
|
WO2024194685A2
(en)
|
2023-03-17 |
2024-09-26 |
Oxitope Pharma B.V. |
Anti-phosphocholine antibodies and methods of use thereof
|
|
WO2024194686A2
(en)
|
2023-03-17 |
2024-09-26 |
Oxitope Pharma B.V. |
Anti-phosphocholine antibodies and methods of use thereof
|
|
WO2024211807A1
(en)
|
2023-04-07 |
2024-10-10 |
Diagonal Therapeutics Inc. |
Hinge-modified bispecific antibodies
|
|
WO2024211796A1
(en)
|
2023-04-07 |
2024-10-10 |
Diagonal Therapeutics Inc. |
Bispecific agonistic antibodies to activin a receptor like type 1 (alk1)
|